EUVIMEDEUVIMED entdecken
Crossref

Real-world Experience of Upadacitinib Reinduction and High-dose Maintenance Therapy in Inflammatory Bowel Disease

Agnes H Y Ho, David Choi, Alex J Mathew, Alexandra McDermott, Zachary Fine, Evan Fear, Natalie K Choi, Russell D Cohen, Sushila R Dalal, Joel Pekow, Noa Krugliak Cleveland, David T Rubin

Clinical Gastroenterology and Hepatology · 2026-03 · 24 (3) · 763-771

DOI: 10.1016/j.cgh.2025.07.042 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Gastroenterology and Hepatology, 2026-03. Verfasst von Agnes H Y Ho und 11 weiteren Autor:innen. Beteiligte Einrichtung: Inflammatory Bowel Disease Center, University of Chicago Medicine, Chicago, Illinois. Hauptthemen laut MEDLINE: Inflammatory Bowel Diseases, Heterocyclic Compounds, 3-Ring, Maintenance Chemotherapy, Crohn Disease. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 22 Literaturangaben. Gefördert von: McDermott.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND & AIMS: Upadacitinib (UPA) is approved for the treatment of moderately to severely active Crohn's disease (CD) or ulcerative colitis (UC). Responders to UPA 45 mg daily (QD) may lose response (LOR) after transition to lower maintenance doses. We describe our real-world experience of LOR, reinduction, and subsequent maintenance with UPA 45 mg QD. METHODS: This is a prospective cohort study of patients with inflammatory bowel disease (IBD) treated with UPA between April 2022 and November 2023. Included patients responded to UPA induction, had LOR after dose reduction, and subsequently received reinduction therapy with 45 mg QD. Clinical, biochemical, radiologic, and endoscopic data were collected; comparative statistics and Kaplan-Meier survival were calculated. RESULTS: A total of 181 patients (79 CD, 83 UC, 6 IBD-Unclassified, 13 ileal pouch anal-anastomosis) responded to UPA 45 mg QD induction and were switched to a lower maintenance dose (30 mg QD, n = 180; 15 mg QD, n = 1), 46 (16 CD, 23 UC, 1 IBD- Unclassified, 6 ileal pouch anal-anastomosis) met the above criteria. They were followed for a median duration 93 weeks (interquartile range [IQR], 62-119 weeks). Relapse occurred at a median of 21 weeks (IQR, 8-46 weeks) after dose reduction. Dose escalation to 45 mg QD for a median of 13 weeks (IQR, 8-36 weeks) recaptured clinical response in 80.4%. Among patients who recaptured response, 19 again reduced to 30 mg or 15 mg. Over a median of 40 weeks (IQR, 22-59 weeks), 93.8% of patients on 45 mg QD maintained remission vs 21.1% who again dropped to 30 mg QD (P < .001). Disease extent and duration did not significantly predict response recapture. Acne/rosacea was the most common adverse event (39%); there were no serious adverse events. CONCLUSIONS: Most patients with IBD who lose response to UPA when dose reduced in maintenance can be recaptured with 45 mg QD. Among these, continuing 45 mg QD for maintenance is effective, and appears safe.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Inflammatory Bowel DiseasesHeterocyclic Compounds, 3-RingMaintenance ChemotherapyCrohn DiseaseColitis, UlcerativeHumansMaleFemaleAdultMiddle AgedProspective StudiesTreatment Outcome

Stichwörter der Autor:innen

Crohn's diseaseUlcerative colitisUpadacitinib

Substanzen

upadacitinibHeterocyclic Compounds, 3-Ring

Autor:innen und Institutionen

  • Inflammatory Bowel Disease Center, University of Chicago Medicine, Chicago, Illinois.
  • Inflammatory Bowel Disease Center, University of Chicago Medicine, Chicago, Illinois. Electronic address: drubin@bsd.uchicago.edu.

Förderung

  • McDermott

Zitieren

APA

Ho, A. H. Y., Choi, D., Mathew, A. J., McDermott, A., Fine, Z., Fear, E., Choi, N. K., Cohen, R. D., Dalal, S. R., Pekow, J., Krugliak Cleveland, N., & Rubin, D. T. (2026). Real-world Experience of Upadacitinib Reinduction and High-dose Maintenance Therapy in Inflammatory Bowel Disease. Clinical Gastroenterology and Hepatology, 24(3), 763-771. https://doi.org/10.1016/j.cgh.2025.07.042

Vancouver

Ho AHY, Choi D, Mathew AJ, McDermott A, Fine Z, Fear E, et al. Real-world Experience of Upadacitinib Reinduction and High-dose Maintenance Therapy in Inflammatory Bowel Disease. Clinical Gastroenterology and Hepatology. 2026;24(3):763-771. doi:10.1016/j.cgh.2025.07.042

BibTeX
@article{Ho2026,
  author = {Ho, Agnes H Y and Choi, David and Mathew, Alex J and McDermott, Alexandra and Fine, Zachary and Fear, Evan and Choi, Natalie K and Cohen, Russell D and Dalal, Sushila R and Pekow, Joel and Krugliak Cleveland, Noa and Rubin, David T},
  title = {Real-world Experience of Upadacitinib Reinduction and High-dose Maintenance Therapy in Inflammatory Bowel Disease},
  journal = {Clinical Gastroenterology and Hepatology},
  year = {2026},
  volume = {24},
  number = {3},
  pages = {763--771},
  doi = {10.1016/j.cgh.2025.07.042}
}
Kostenlos starten →